Abstract
Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor 1 were optimized for metabolic stability. The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clinically derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK). FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis. The discovery of the clinical stage, dual FAK/ALK inhibitor 27b, including details surrounding SAR, in vitro/in vivo pharmacology, and pharmacokinetics, is reported herein.
MeSH terms
-
Administration, Oral
-
Anaplastic Lymphoma Kinase
-
Animals
-
Benzamides / administration & dosage
-
Benzamides / chemistry
-
Benzamides / pharmacology*
-
Benzocycloheptenes / administration & dosage
-
Benzocycloheptenes / chemistry
-
Benzocycloheptenes / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation
-
Dose-Response Relationship, Drug
-
Drug Discovery*
-
Drug Screening Assays, Antitumor
-
Female
-
Focal Adhesion Kinase 1 / antagonists & inhibitors*
-
Focal Adhesion Kinase 1 / metabolism
-
Humans
-
Mice
-
Mice, Nude
-
Mice, SCID
-
Models, Molecular
-
Molecular Structure
-
Neoplasms, Experimental / drug therapy
-
Neoplasms, Experimental / pathology
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Receptor Protein-Tyrosine Kinases / metabolism
-
Structure-Activity Relationship
Substances
-
Benzamides
-
Benzocycloheptenes
-
CEP-37440
-
Protein Kinase Inhibitors
-
ALK protein, human
-
Alk protein, mouse
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases
-
Focal Adhesion Kinase 1
-
PTK2 protein, human